The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes
NCT ID: NCT00678522
Last Updated: 2008-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
25 participants
INTERVENTIONAL
2007-09-30
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects
NCT00344955
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy
NCT01208701
Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients
NCT01013103
Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00124397
Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion
NCT01126684
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
80 mg atorvastatin daily on two following days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. estimated GFR between 30 and 90 ml/min
3. BMI\<35
4. Fertile women had to use oral contraceptives or IUD
5. HbA1c\< 10%
6. Urine-albumin\<1,5 g/l
Exclusion Criteria
2. Cerobrovascular insult or other disease of the brain
3. Insufficiency of the heart or lungs
4. Liverdisease with ALAT \> 200 U/L
5. hemoglobin \< 7,0 mmol/l
6. Cancer
7. Alcohol abuse
8. Medical treatment with psycopharmaca or/and analgetics
9. Pregnancy and breast feeding, 10 blood donation one month before the study.
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Research
AMBIG
Regional Hospital Holstebro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erling B. Pedersen, Professor
Role: PRINCIPAL_INVESTIGATOR
Dept. of medical reaserch, Holstebro Hospital, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Reseach, Holstebro Hospital
Holstebro, , Denmark
Department of Medical Research, Holstebro Hospital
Holstebro, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MED.RES.HOS.2006.04.LP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.